Protocol Ledger

NCT04175600 · Phase III · ACTIVE NOT RECRUITING

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

Interventional Phase III clinical trial protocol NCT04175600 sponsored by Johnson & Johnson / Janssen in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-16 Enrollment: 138 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04175600
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)138 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04175600
Protocol FieldVerified Registry Value
NCT IdentifierNCT04175600
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment138 participants (ACTUAL)
Registered Start Date2020-01-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI